Journal of Renal Nutrition
Volume 15, Issue 1 , Pages 99-104 , January 2005

Kidney disease as an independent risk factor for cardiovascular events

  • Jayant Kumar, MD

      Affiliations

    • Department of Internal Medicine, Division of Nephrology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR.
    • ,
  • Sudhir V. Shah, MD

      Affiliations

    • Department of Internal Medicine, Division of Nephrology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR.
    • Corresponding Author InformationAddress reprint requests to Sudhir V. Shah, MD, University of Arkansas for Medical Sciences, Department of Internal Medicine, Division of Nephrology, 4301 W Markham St, Slot 501, Little Rock, AR 72205.

References 

  1. Sarnak MJ , Levey AS , Schoolwerth AC , et al.   Kidney disease as a risk factor for development of cardiovascular disease (A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention) . Circulation . 2003;108:2154–2169
  2. Wilson PW , D’Agostino RB , Levy D , et al.   Prediction of coronary heart disease using risk factor categories . Circulation . 1998;97:1837–1847
  3. Anderson KM , Wilson PW , Odell PM , et al.   An updated coronary risk profile. A statement for health professionals . Circulation . 1991;83:356–362
  4. K/DOQI clinical practice guidelines for chronic kidney disease (Evaluation, classification, and stratification) . Am J Kidney Dis . 2002;39(suppl 1):S1–S266
  5. Miettinen H , Haffner SM , Lehto S , et al.   Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and noninsulin-dependent diabetic subjects . Stroke . 1996;27:2033–2039
  6. Pontremoli R , Leoncini G , Ravera M , et al.   Microalbuminuria, cardiovascular, and renal risk in primary hypertension . J Am Soc Nephrol . 2002;13(suppl 3):S169–S172
  7. Gerstein H , Mann JFE , Yi Q , et al.   HS (Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals) . JAMA . 2001;286:421–426
  8. Schmitz KH , Arnett DK , Bank A , et al.   Arterial distensibility and physical activity in the ARIC study . Med Sci Sports Exerc . 2001;33:2065–2071
  9. Mann JFE , Gerstein H , Pogue J , et al.   Renal insufficiency as a predictor of cardiovascular outcomes and the impact of Ramipril (The HOPE randomized trial) . Ann Intern Med . 2001;134:629–636
  10. Mann JF , Gerstein HC , Dulau-Florea I , et al.   Cardiovascular risk in patients with mild renal insufficiency . Kidney Int Suppl . 2003;84:S192–S196
  11. The Hypertension Detection and Follow-up Program Cooperative Group Shulman NB , Ford CE , Hall WD , et al.   Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program . Hypertension . 1989;13(suppl):93
  12. Ruilope LM , Salvetti A , Jamerson K , et al.   Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study . J Am Soc Nephrol . 2001;12:218–225
  13. Foley RN , Parfrey PS , Sarnak MJ . Clinical epidemiology of cardiovascular disease in chronic renal disease . Am J Kidney Dis . 1998;32:S112–S119
  14. Liu Y , Coresh J , Eustace JA , et al.   Association between cholesterol level and mortality in dialysis patients (Role of inflammation and malnutrition) . JAMA . 2004;291:451–459
  15. Rigatto C . Clinical epidemiology of cardiac disease in renal transplant recipients . Semin Dial . 2003;16:106–110
  16. Foley RN , Parfrey PS , Harnett JD , et al.   The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease . Am J Kidney Dis . 1996;28:53–61
  17. Chertow GM . Slowing the progression of vascular calcification in hemodialysis . J Am Soc Nephrol . 2003;14:S310–S314
  18. Venugopal SK , Devaraj S , Yuhanna I , et al.   Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells . Circulation . 2002;106:1439–1441
  19. Devaraj S , Xu DY , Jialal I . C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells (Implications for the metabolic syndrome and atherothrombosis) . Circulation . 2003;107:398–404
  20. Stenvinkel P , Heimburger O , Paultre F , et al.   Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure . Kidney Int . 1999;55:1899–1911
  21. Yeun JY , Levine RA , Mantadilok V , et al.   C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients . Am J Kidney Dis . 2000;35:469–476
  22. Bro S , Moeller F , Andersen CB , et al.   Increased expression of adhesion molecules in uremic atherosclerosis in apolipoprotein-e-deficient mice . J Am Soc Nephrol . 2004;15:1495–1503
  23. Drueke T , Witko-Sarsat V , Massy Z , et al.   Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease . Circulation . 2002;106:2212–2217
  24. Descamps-Latscha B , Witko-Sarsat V . Oxidative stress in chronic renal failure and hemodialysis . Nephrologie . 2003;24:377–379
  25. Vallance P , Leone A , Calver A , et al.   Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure . Lancet . 1992;339:572–575
  26. Kraus LM , Kraus APJ . The search for the uremic toxin (The case for carbamoylation of amino acids and proteins) . Wien Klin Wochenschr . 1998;110:521–530
  27. Kraus LM , Kraus AP . Carbamylation of amino acids and proteins in uremia . Kidney Int . 2001;59:S102–S107
  28. Ok E , Basnakian AG , Shah SV . Increased expression of adhesion molecules induced by carbamylated LDL . J Am Soc Nephrol . 2002;13:340A; (abstr)
  29. Eikelboom JW , Hankey GJ . Associations of homocysteine, C-reactive protein and cardiovascular disease in patients with renal disease . Curr Opin Nephrol Hypertens . 2001;10:377–383
  30. Wrone EM , Hornberger JM , Zehnder JL , et al.   Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease . J Am Soc Nephrol . 2004;15:420–426
  31. Leskinen Y , Lehtimaki T , Loimaala A , et al.   Homocysteine and carotid atherosclerosis in chronic renal failure—The confounding effect of renal function . Atherosclerosis . 2004;175:315–323
  32. Muntner P , Hamm LL , Kusek JW , et al.   The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease . Ann Intern Med . 2004;140:9–17
  33. Wanner C , Krane V , Metzger T , et al.   Lipid changes and statins in chronic renal insufficiency and dialysis . J Nephrol . 2001;14(suppl 4):S76–S80
  34. Boaz M , Smetana S , Weinstein T , et al.   Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE) (Randomised placebo-controlled trial) . Lancet . 2000;356:1213–1218
  35. Tepel M , van der Giet M , Statz M , et al.   The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure (A randomized, controlled trial) . Circulation . 2003;107:992–995

PII: S1051-2276(04)00238-9

doi: 10.1053/j.jrn.2004.09.032

Journal of Renal Nutrition
Volume 15, Issue 1 , Pages 99-104 , January 2005

Article Tools

* Image Usage & Resolution